Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001615774-17-006474
Filing Date
2017-11-13
Accepted
2017-11-13 10:33:35
Documents
56
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q s108065_10q.htm 10-Q 507296
2 EXHIBIT 31.1 s108065_ex31-1.htm EX-31.1 15771
3 EXHIBIT 32.1 s108065_ex32-1.htm EX-32.1 6099
  Complete submission text file 0001615774-17-006474.txt   3710949

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE bthe-20170930.xml EX-101.INS 681509
5 XBRL SCHEMA FILE bthe-20170930.xsd EX-101.SCH 36959
6 XBRL CALCULATION FILE bthe-20170930_cal.xml EX-101.CAL 50595
7 XBRL DEFINITION FILE bthe-20170930_def.xml EX-101.DEF 185289
8 XBRL LABEL FILE bthe-20170930_lab.xml EX-101.LAB 327129
9 XBRL PRESENTATION FILE bthe-20170930_pre.xml EX-101.PRE 261650
Mailing Address 354 MERRIMACK STREET #4 LAWRENCE MA 01843
Business Address 354 MERRIMACK STREET #4 LAWRENCE MA 01843 (603) 935-9799
Boston Therapeutics, Inc. (Filer) CIK: 0001473579 (see all company filings)

EIN.: 270801073 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-54586 | Film No.: 171193990
SIC: 2834 Pharmaceutical Preparations